• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巴西多发性硬化症的患病率:一项系统综述。

Prevalence of multiple sclerosis in Brazil: A systematic review.

作者信息

da Gama Pereira Ana Beatriz Calmon Nogueira, Sampaio Lacativa Maria Clinete, da Costa Pereira Fernanda Ferreira Chaves, Papais Alvarenga Regina Maria

机构信息

Programa de Pós-Graduação em Neurologia da Universidade Federal do Estado do Rio de Janeiro- UNIRIO, Brasil; Universidade Severino Sombra, Vassouras, Brasil.

Programa de Pós-Graduação em Neurologia da Universidade Federal do Estado do Rio de Janeiro- UNIRIO, Brasil; Hospital dos Servidores do Estado, Rio de Janeiro, Brasil.

出版信息

Mult Scler Relat Disord. 2015 Nov;4(6):572-9. doi: 10.1016/j.msard.2015.08.004. Epub 2015 Aug 15.

DOI:10.1016/j.msard.2015.08.004
PMID:26590664
Abstract

Epidemiological studies of multiple sclerosis (MS) conducted in Latin America have revealed prevalence rates of this disease from low to medium. The aim of this study was to gather and analyze surveys on prevalence conducted in Brazil, noting its variability in different regions. Systematic review was held in electronic databases and manual search in abstracts concerning ECTRIMS, LACTRIMS and Brazilian Congress of Neurology. Nineteen studies made reference to prevalence rates that ranged from 1.36/100,000 to 27.2/100.000 inhabitants. More studies on the epidemiology of MS in Brazil will be needed for a better assessment of its prevalence and profile.

摘要

在拉丁美洲进行的多发性硬化症(MS)流行病学研究显示,该疾病的患病率处于低至中等水平。本研究的目的是收集并分析在巴西进行的患病率调查,注意其在不同地区的差异。我们在电子数据库中进行了系统综述,并在有关ECTRIMS、LACTRIMS和巴西神经病学大会的摘要中进行了人工检索。19项研究提到患病率在每10万居民1.36至27.2例之间。为了更好地评估巴西MS的患病率和特征,还需要更多关于MS流行病学的研究。

相似文献

1
Prevalence of multiple sclerosis in Brazil: A systematic review.巴西多发性硬化症的患病率:一项系统综述。
Mult Scler Relat Disord. 2015 Nov;4(6):572-9. doi: 10.1016/j.msard.2015.08.004. Epub 2015 Aug 15.
2
Epidemiology of multiple sclerosis in Iran: a systematic review.伊朗多发性硬化症的流行病学:系统评价。
Eur Neurol. 2013;70(5-6):356-63. doi: 10.1159/000355140. Epub 2013 Nov 2.
3
Memory rehabilitation for people with multiple sclerosis.针对多发性硬化症患者的记忆康复治疗。
Cochrane Database Syst Rev. 2016 Mar 23;3:CD008754. doi: 10.1002/14651858.CD008754.pub3.
4
MS and Disability Progression in Latin America, Africa, Asia and the Middle East: A Systematic Review.拉丁美洲、非洲、亚洲和中东的多发性硬化症与残疾进展:系统评价。
Mult Scler Relat Disord. 2021 Jun;51:102885. doi: 10.1016/j.msard.2021.102885. Epub 2021 Mar 9.
5
The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review.拉丁美洲和加勒比地区多发性硬化症的流行病学:系统评价。
Mult Scler. 2013 Jun;19(7):844-54. doi: 10.1177/1352458512462918. Epub 2012 Oct 8.
6
Incidence and prevalence of multiple sclerosis in the Americas: a systematic review.美洲多发性硬化症的发病率和患病率:系统评价。
Neuroepidemiology. 2013;40(3):195-210. doi: 10.1159/000342779. Epub 2013 Jan 24.
7
Incidence and prevalence of multiple sclerosis in Europe: a systematic review.欧洲多发性硬化症的发病率和患病率:系统评价。
BMC Neurol. 2013 Sep 26;13:128. doi: 10.1186/1471-2377-13-128.
8
A systematic review of the epidemiology of multiple sclerosis in South America.南美洲多发性硬化症流行病学的系统评价。
Eur J Neurol. 2008 Dec;15(12):1273-8. doi: 10.1111/j.1468-1331.2008.02330.x.
9
Multiple sclerosis in Brazil: A systematic review.巴西的多发性硬化症:一项系统综述。
Clin Neurol Neurosurg. 2016 Dec;151:24-30. doi: 10.1016/j.clineuro.2016.07.011. Epub 2016 Sep 20.
10
Multiple sclerosis epidemiology in Asia and Oceania; A systematic review and meta-analysis.亚洲和大洋州多发性硬化症的流行病学; 系统评价和荟萃分析。
Mult Scler Relat Disord. 2021 Sep;54:103119. doi: 10.1016/j.msard.2021.103119. Epub 2021 Jun 30.

引用本文的文献

1
Could rituximab revolutionize multiple sclerosis treatment in Brazil? The missed opportunity for fewer relapses and lower costs.利妥昔单抗能否彻底改变巴西的多发性硬化症治疗现状?错失减少复发和降低成本的机会。
Lancet Reg Health Am. 2025 Jul 1;49:101171. doi: 10.1016/j.lana.2025.101171. eCollection 2025 Sep.
2
The impact of multiple sclerosis on wellbeing, productivity, and societal relations.多发性硬化症对幸福感、生产力和社会关系的影响。
Arq Neuropsiquiatr. 2025 May;83(5):1-8. doi: 10.1055/s-0045-1809400. Epub 2025 Jun 20.
3
Severity of white matter microstructural damage in a Brazilian relapsing-remitting multiple sclerosis cohort: A possible window to optimize treatment.
巴西复发缓解型多发性硬化症队列中白质微观结构损伤的严重程度:优化治疗的一个可能窗口。
Neuroradiol J. 2024 Feb;37(1):60-67. doi: 10.1177/19714009231212372. Epub 2023 Nov 1.
4
Prevalence of fibromyalgia in a Brazilian series of patients with multiple sclerosis.巴西多发性硬化症患者系列中纤维肌痛的患病率。
Arq Neuropsiquiatr. 2023 Sep;81(9):803-808. doi: 10.1055/s-0043-1772673. Epub 2023 Oct 4.
5
Role of Cytokines, Chemokines and IFN-γ IL-17 Double-Positive CD4 T Cells in Patients with Multiple Sclerosis.细胞因子、趋化因子及IFN-γ IL-17双阳性CD4 T细胞在多发性硬化症患者中的作用
Biomedicines. 2022 Aug 24;10(9):2062. doi: 10.3390/biomedicines10092062.
6
Differential diagnosis of demyelinating diseases: what's new?脱髓鞘疾病的鉴别诊断:有哪些新进展?
Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):137-142. doi: 10.1590/0004-282X-ANP-2022-S109.
7
Effect of 12 weeks of aquatic strength training on individuals with multiple sclerosis.12 周水上力量训练对多发性硬化症患者的影响。
Arq Neuropsiquiatr. 2022 May;80(5):505-509. doi: 10.1590/0004-282X-ANP-2020-0541.
8
Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study.巴西初治复发缓解型多发性硬化症的有效性:一项 16 年非同期队列研究。
PLoS One. 2020 Sep 2;15(9):e0238476. doi: 10.1371/journal.pone.0238476. eCollection 2020.
9
State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis.多发性硬化症研究与医学管理的现状及未来挑战:深入了解第五届国际多发性硬化症波尔图大会
Neurol Ther. 2020 Dec;9(2):281-300. doi: 10.1007/s40120-020-00202-7. Epub 2020 Jul 14.
10
Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach.巴西公共医疗体系中,用于 RRMS 二线治疗的那他珠单抗与芬戈莫德的年化住院率:基于索赔数据库的研究方法。
PLoS One. 2020 Mar 2;15(3):e0229768. doi: 10.1371/journal.pone.0229768. eCollection 2020.